Agencia Lei Va Hong
Concise Prescribing Info
Etelcalcetide HCl
Secondary hyperparathyroidism (SHPT) in adult patients w/ chronic kidney disease (CKD) on haemodialysis therapy.
Dosage/Direction for Use
Initially 5 mg 3x wkly by bolus or IV inj. Dose titration should be made so that doses are individualized between 2.5 & 15 mg. The dose may be increased in 2.5 or 5 mg increments no more frequently than every 4 wk to max dose of 15 mg 3x wkly. Administer Parsabiv into the venous line of the dialysis circuit at the end of haemodialysis treatment during rinse-back or IV after rinse-back.
Hypersensitivity. Do not initiate treatment if corrected serum Ca is less than the lower limit of the normal range.
Special Precautions
Risk of hypocalcaemia. Measure serum Ca prior to treatment initiation, w/in 1 wk of initiation or dose adjustment & every 4 wk during treatment. Ventricular arrhythmia & QT prolongation secondary to hypocalcaemia. Patients w/ history of convulsion disorder or CHF. Risk of adynamic bone in patients w/ PTH <100 pg/mL. +ve for binding Abs in patients w/ SHPT. Co-administration w/ other medicinal products known to lower serum Ca. Hepatic impairment. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Decreased blood Ca; nausea, vomiting, diarrhoea; muscle spasms. Hypocalcaemia, hyperkalaemia, hypophosphataemia; headache, paraesthesia; QT prolongation, worsening heart failure; hypotension; myalgia.
Drug Interactions
Increased risk of severe hypocalcaemia w/ medicinal products known to reduce serum Ca levels. Patients receiving Parsabiv should not be given cinacalcet.
MIMS Class
Other Agents Affecting Metabolism
ATC Classification
H05BX04 - etelcalcetide ; Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
Parsabiv soln for inj 2.5 mg/0.5 mL
10 × 1's
Parsabiv soln for inj 5 mg/mL
10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in